Inactive Instrument

Analyst Reco. Reata Pharmaceuticals, Inc.

Equities

RETA

US75615P1030

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

Citigroup Downgrades Reata Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $172.50 From $127	23-08-01	MT
Barclays Downgrades Reata Pharmaceuticals to Equalweight From Overweight, Adjusts Price Target to $172 From $110	23-08-01	MT
Ladenburg Thalmann Downgrades Reata Pharmaceuticals to Neutral From Buy, Raises Price Target to $172.50 From $122	23-07-31	MT
Jefferies Downgrades Reata Pharmaceuticals to Hold From Buy, Adjusts Price Target to $172.50 From $104	23-07-31	MT
Wedbush Raises Biogen's PT to $276 From $268 Following $7.3B Purchase Bid for Reata Pharmaceuticals, Keeps Neutral Rating	23-07-31	MT
Cantor Fitzgerald Adjusts Price Target on Reata Pharmaceuticals to $145 From $110, Maintains Overweight Rating	23-07-24	MT
TD Cowen Initiates Reata Pharmaceuticals at Outperform With $140 Price Target	23-07-06	MT
Ladenburg Thalmann Adjusts Price Target on Reata Pharmaceuticals to $122 From $104, Maintains Buy Rating	23-06-29	MT
Barclays Raises Price Target on Reata Pharmaceuticals to $110 From $98, Maintains Overweight Rating	23-06-28	MT
SVB Securities Upgrades Reata Pharmaceuticals to Outperform From Market Perform, Adjusts Price Target to $115 From $80	23-06-12	MT
Barclays Adjusts Price Target on Reata Pharmaceuticals to $98 From $90, Keeps Overweight Rating	23-05-11	MT
Stifel Raises Price Target on Reata Pharmaceuticals to $115 From $105, Maintains Buy Rating	23-04-13	MT
Cantor Fitzgerald Adjusts Reata Pharmaceuticals Price Target to $138 From $121, Maintains Overweight Rating	23-03-27	MT
Cantor Fitzgerald Adjusts Price Target on Reata Pharmaceuticals to $121 From $61, Maintains Overweight Rating	23-03-01	MT
Goldman Sachs Raises Price Target on Reata Pharmaceuticals to $185 From $117, Maintains Buy Rating	23-03-01	MT
Citigroup Adjusts Price Target on Reata Pharmaceuticals to $120 From $53, Maintains Buy Rating	23-03-01	MT
Barclays Raises Price Target on Reata Pharmaceuticals to $90 From $50, Maintains Overweight Rating	23-03-01	MT
Goldman Sachs Adjusts Price Target on Reata Pharmaceuticals to $115 From $86, Maintains Buy Rating	22-11-28	MT
Goldman Sachs Adjusts Price Target on Reata Pharmaceuticals to $86 From $76, Maintains Buy Rating	22-11-09	MT
Citigroup Adjusts Price Target on Reata Pharmaceuticals to $53 From $51, Maintains Buy Rating	22-11-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Reata Pharmaceuticals, Inc.

Equities

RETA

US75615P1030

Analyst Reco.

Filters